A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Clinical trial NCT07477587 · RECRUITING
Trial details
- NCT number
- NCT07477587
- Sponsor
- Shanghai Henlius Biotech
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-27
- Primary completion
- 2027-05-25
- Enrollment
- 258
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.